Temetex in the treatment of steroid-responsive dermatoses.
Five hundred and seventy-five patients with various steroid-responsive dermatoses were studied for up to six weeks in eighty-eight separate general practices using a new topical corticosteroid. Temetex (diflucortolone valerate 0-1%). It was concluded that Temetex is both effective and well tolerated in a wide variety of conditions, especially eczema and psoriasis. It was also shown that a large-scale general practice trial can be carried out efficiently with a very high compliance rate.
D000287:Administration, Topical; D003872:Dermatitis / Q000188:drug therapy*; D004485:Eczema / Q000188:drug therapy; D005260:Female; D005448:Fluocortolone / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D007402:Intertrigo / Q000188:drug therapy; D008297:Male; D011244:Pregnadienediols / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012393:Rosacea / Q000188:drug therapy
D011244:Pregnadienediols; D005448:Fluocortolone